Stapokibart’s clinical effectiveness in treating moderate-to-severe bullous pemphigoid in the elderly

ObjectiveBullous pemphigoid (BP) is the most common autoimmune blistering disease in the elderly, for whom conventional systemic corticosteroids and immunosuppressants pose significant safety risks due to age-related comorbidities, leading to infections, osteoporosis, and metabolic disorders. While stapokibart, a novel IL-4Rα inhibitor, holds promise for type 2 inflammatory diseases, clinical evidence regarding its efficacy in BP is currently lacking.

Therefore, this study aims to observe the clinical efficacy and long-term safety of stapokibart in the treatment of moderate-to-severe BP in the elderly.MethodsThis single-center, retrospective, uncontrolled case series included 15 elderly patients with moderate-to-severe BP. In addition to conventional topical glucocorticoids or combined systemic therapy, patients received an initial dose of 600 mg stapokibart, followed by 300 mg every 2 weeks.

Dosage adjustments were made based on patients’ clinical responses after 16 weeks. The core treatment period was 24 weeks, with a subsequent post-treatment follow-up duration ranging from 4 to 34 weeks (mean 18.78 ± 11.54 weeks).

The primary outcome was explicitly defined as the achievement of disease control at 4 weeks.